Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease

Heart

Volumn 97, Issue 15, 2011, Pages 1215-1221

  Grandi, Norma Christine ^a   Breitling, Lutz Philipp ^a   Hahmann, Harry ^b   Wüsten, Bernd ^c   März, Winfried ^d   Rothenbacher, Dietrich ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Klinik Schwabenland   (Germany)

^c Klinik Am Südpark   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GERMANY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STROKE;

ADULT; AGE DISTRIBUTION; AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 79960196396     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.223529     Document Type: Article

References (37)

1. Malluche HH, Koszewski N, Monier-Faugere MC, et al. Influence of the parathyroid glands on bone metabolism. Eur J Clin Invest 2006;36(Suppl 2):23-33. (Pubitemid 44050607)
2. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003;10:309-22. (Pubitemid 36758657)
3. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006;99:1044-59. (Pubitemid 44729928)
4. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008;6:77-83.
5. Fraser WD. Hyperparathyroidism. Lancet 2009;374:145-58.
6. Hagstrom E, Lundgren E, Lithell H, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf) 2002;56:253-60. (Pubitemid 34233964)
7. Lundgren E, Ljunghall S, Akerstrom G, et al. Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 1998;124:980-5; discussion 5-6.
8. Schluter KD, Wingender E, Tegge W, et al. Parathyroid hormone-related protein antagonizes the action of parathyroid hormone on adult cardiomyocytes. J Biol Chem 1996;271:3074-8. (Pubitemid 26060525)
9. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997;82:106-12. (Pubitemid 27021279)
10. Gennari C, Nami R, Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Miner Electrolyte Metab 1995;21:77-81.
11. Hulter HN, Melby JC, Peterson JC, et al. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986;2:360-70.
12. Ljunghall S, Palmer M, Akerstrom G, et al. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. Eur J Clin Invest 1983;13:373-7. (Pubitemid 13014013)
13. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002;19:958-61. (Pubitemid 35356924)
14. Lundgren E, Lind L, Palmer M, et al. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001;130:978-85. (Pubitemid 34014563)
15. Ogard CG, Engholm G, Almdal TP, et al. Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004;28:108-11.
16. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:2765-71.
17. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004;11:69-74. (Pubitemid 38388927)
18. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010;31:1591-8.
19. Sambrook PN, Chen JS, March LM, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab 2004;89:5477-81. (Pubitemid 39518428)
20. Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet 2006;367:69-78.
21. Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93. (Pubitemid 44288987)
22. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006;166:2455-60.
23. von Eynatten M, Hamann A, Twardella D, et al. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 2008;29:1307-15. (Pubitemid 351768129)
24. Bergstralh E, Therneau T, Lennon R. SAS Macro %SCHOEN. http://mayoresearch.mayo.edu/biostat/sasmacros.cfm (accessed 30 Aug 2010).
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.
26. Sauerbrei W, Meier-Hirmer C, Benner A, et al. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 2006;50:3464-85. (Pubitemid 43794958)
27. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010;9:709-15.
28. Perkovic V, Hewitson TD, Kelynack KJ, et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003;26:27-33. (Pubitemid 36438798)
29. London GM, Marchais SJ, Guerin AP, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525-31. (Pubitemid 41531842)
30. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77:93-100.
31. Grimnes G, Almaas B, Eggen AE, et al. Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed. Eur J Endocrinol 2010;163:339-48.
32. Grande G. Genderspezifische aspekte der gesundheitsversorgung und rehabilitation nach herzinfarkt. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008;51:36-45.
33. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart 2009;95:395-8.
34. Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007;37:915-22. (Pubitemid 350151180)
35. Kooienga L, Fried L, Scragg R, et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009;53:408-16.
36. Zhu K, Devine A, Dick IM, et al. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab 2008;93:743-9. (Pubitemid 351398548)
37. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008;73:1355-63. (Pubitemid 351770491)